New eye drops aim to soothe dry eyes in clinical trial

NCT ID NCT07369375

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether VMX eye drops can improve tear film stability and reduce dry eye symptoms compared to standard care. About 76 adults with mild to moderate dry eye disease will receive either VMX drops or a control. The main goal is to see if the drops help eyes stay moist longer and ease discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 76 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with an age of ≥ 18 and ≤ 80 years * Patients with a diagnosis of Dry Eye (mild/moderate) with at least one of the following: * Tear Osmolarity \>308 mOsm/L * TBUT \< 10 seconds * Schirmer I test ≥ 5 mm and ≤ 14 mm at 5 minutes * Patients not treated with artificial tears for at least 7 days * Patients not treated with artificial tears for at least 7 days Exclusion Criteria: * Use of systemic medications which may affect a dry eye condition within 1 month prior to study enrolment (e.g. low-dose aspirin, antihistamines, decongestants, antipsychotics, parkinsonism medications, anticholinergics, oral isotretinoin, and oral diazepam) * Patients with a score of ≤ 4 mm at 5 minutes on the Schirmer I test * Patients that suffer of ocular allergy pathology (seasonal and chronic) * Ongoing ocular or systemic infectious conditions * Use of topical ocular therapies that cannot be suspended for the entire duration of the study * Use of topical antibiotics and or corticosteroids within 15 days prior to study enrolment * Use of systemic antibiotics and or corticosteroids within 1 month prior to study enrolment * Any intraocular surgery in the past 12 months or require any intraocular surgery during the study * Acute and Chronic Conjunctival Disease * Eyelid surgery within the 6 months prior to study enrolment * Presence of congenitally absent lacrimal or Meibomian glands or have any obstructive disease of the lacrimal glands * History of ocular herpetic keratitis or active blepharitis in the 4 weeks prior to study enrolment * History of autoimmune diseases * Inflammations or abnormalities in the eyelid, in accordance with PI's clinical judgment * History of corneal diseases, as keratoconus * History of corneal transplant in one or both eyes * Keratinization of the eyelid margin * History of Sjögren's syndrome * History of corneal trauma in the last 4 weeks prior to study enrolment * Patients who are unwilling to discontinue all artificial tears and use only the study product ad indicated for the duration of the study * Inability to self-administer study medications * Women of childbearing potential who are pregnant, breast feeding, plan to become pregnant during the study, or not using adequate birth control methods to prevent pregnancy throughout the study. * Any hypersensitivity to the use of the study product formulations or an allergy to any ingredients contained within product formulation * Participation in other clinical studies involving drugs or devices within 30 days prior to study enrolment. * Patients legally or mentally incapacitated unable to give informed consent for the participation in this trial * Patients unable or unwilling to comply with appointments or all protocol requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye disease (DED) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.